Iovance Biotherapeutics Shares Surge 33% Following Revenue Guidance Increase
Iovance Biotherapeutics, Inc. (IOVA) shares jumped 33% after the company raised its fiscal year 2026 revenue outlook to between $410 million and $420 million. This adjustment reflects strong U.S. demand for its products Amtagvi and Proleukin.